US · Healthcare · Healthcare Plans
EPS came in at 0.06 against a street estimate of 0.05 — a beat of 20.0%.
Analysts rate Clover Health Investments Corp a buy (2 buy, 2 hold, 0 sell out of 4) with an average price target of $5.38.
CONFIDENT CLOV delivered 48% MA membership growth, $67M YoY net income increase, and raised FY26 guidance across all metrics. Confidence anchored on cohort maturation under Clover Assistant, not just 4.5-Star rating win. Q2 2026 Management emphasized disciplined, concentrated growth in core NJ and GA markets where clinical engagement and unit economics strongest. Analysts pressed on Clover Assistant coverage % in recent cohorts, 2027 bid strategy amid Stars ruling, and competitor disruption assumptions. Management clarified low-60s CA engagement in new cohorts with upside, disciplined bidding tied to cohort maturation offsets, and expects continued disruption factored into projections. 2026-08-05…
Full summary in the app.
| Fund | Stake |
|---|---|
| BlackRock Inc | 6.61% |
| Vanguard Capital Management, LLC | 3.40% |
| Geode Capital Management, LLC | 2.04% |
| State Street Corp | 1.92% |
| Nuveen, LLC | 1.18% |
| Charles Schwab Investment Management Inc | 1.04% |
| Vanguard Portfolio Management, LLC | 0.84% |
| Northern Trust Corp | 0.71% |
| Document | Date |
|---|---|
| Reg FD disclosure · Q4 2026 HEADLINE NUMBERS • CMS awarded Clover Health’s Medicare Advantage PPO plans a 5-Star rating for 2027. • Clover’s HMO Medicare Advantage plan receive | 2026-10-09 |
| Board / officer change · Q3 2026 CLOVER HEALTH INVESTMENTS, CORP. – FORM 8-K SUMMARY HEADLINE NUMBERS • Board expanded to 9 directors (from 7) with appointment of 2 new Class directo | 2026-09-24 |
| Reg FD disclosure · Q3 2026 CLOVER HEALTH INVESTMENTS, CORP. (CLOV) - FORM 8-K SUMMARY HEADLINE NUMBERS • No specific financial metrics disclosed in this filing • Document date | 2026-08-20 |
| Quarterly report · Q2 2026 CLOVER HEALTH INVESTMENTS, CORP. - Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Total Revenues (H1 2026): $1,492,356 thousand ($1.49 billion), up 59% fro | 2026-08-07 |
| Results announced · Q3 2026 CLOVER HEALTH Q2 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Q2 2026 GAAP Net Income: $28 million (vs. -$10.6 million loss in Q2 2025), improvement of | 2026-08-05 |
| Company announcement · Q3 2026 CLOVER HEALTH INVESTMENTS, CORP. – FORM 8-K SUMMARY HEADLINE NUMBERS • No material financial impact reported from the cybersecurity incident as of f | 2026-07-17 |
| Company announcement · Q2 2026 CLOVER HEALTH INVESTMENTS, CORP. – FORM 8-K SUMMARY HEADLINE NUMBERS • PPO Medicare Advantage Contract (H5141): Star rating recalculated from 3.5 St | 2026-06-18 |
| Quarterly report · Q1 2026 CLOVER HEALTH INVESTMENTS, CORP. - Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Net Income: $27.3 million for Q1 2026 vs. net loss of $1.3 million in Q1 | 2026-05-08 |
Readable in the app.
| Announcement | Date |
|---|---|
| Medicare Advantage Star Ratings increased for two contracts Clover Health received favorable rating increases for its Medicare Advantage plans following a court judgment. The company's PPO plan (H5141) had its 2026 Star Rating recalculated upward fro | 2026-06-18 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Clover Health Investments Corp — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-18.